How Long Till Mounjaro Leaves Your System

What the half-life figure actually tells us, and what it doesn't

The Mounjaro SmPC, published on the electronic Medicines Compendium, documents tirzepatide's elimination half-life at around five days. Half-life is the time taken for blood concentration to halve. After one half-life you still have 50% of the dose circulating; after two, 25%; after five, you're below 3%, which is the conventional threshold for describing a medicine as effectively cleared. Multiply five days by five and you reach roughly 25 days, or just under four weeks. Some pharmacologists round this to five weeks to account for individual variability.

That variability is real. People with reduced kidney function clear tirzepatide more slowly. Higher body weight increases the volume of distribution (the medicine spreads into more tissue) which can lengthen the tail end of elimination. Age and lean muscle mass play smaller roles. No single figure fits everyone precisely, which is exactly why timing decisions around surgery, conception or a switch to another medicine belong in a conversation with your prescriber rather than in a calculator.

One practical detail worth noting: because tirzepatide accumulates slightly over the first few weeks of treatment before reaching steady state, stopping abruptly from a higher maintenance dose means blood levels fall from a higher starting point than they would from a 2.5 mg starter dose. The washout curve looks similar in shape but takes longer to reach zero. You can read more about how the medicine works from first dose onwards on our page covering how long Mounjaro takes to work.

When effects fade versus when the drug is gone

Blood levels and clinical effects are not the same thing. The GLP-1 and GIP receptors that tirzepatide activates become less engaged as concentrations fall, so appetite returns and gastric emptying speeds back up before the last molecule has cleared. Most people notice hunger increasing within one to two weeks of their final injection, sometimes sooner at lower doses where the therapeutic window is narrower.

Weight regain follows a similar pattern. Clinical trial data from the SURMOUNT programme show that participants who stopped tirzepatide after achieving significant weight loss regained a meaningful proportion of that weight over the following year, because the biological drivers of appetite are not permanently altered. The medicine works while it is present; stopping it removes that effect. This is one reason our prescribers treat the stopping decision as carefully as the starting one.

If you are mid-treatment and want to understand what the current evidence says about tirzepatide as a licensed medicine for weight management in the UK, the Mounjaro overview covers the full picture. For specific questions about clearance timelines that differ from the standard five-day half-life (perhaps because of a health condition or another medicine) the nume FAQs and our aftercare team are the right place to start.

Clinical situations where clearance timing genuinely matters

Three situations come up in practice where knowing the washout period has direct consequences.

Surgery and anaesthesia. NHS England advises that anyone taking tirzepatide should tell their surgical team and anaesthetist before any procedure. Slowed gastric emptying increases the risk of aspiration under general anaesthesia. Your surgical team will advise how far in advance to stop; if you want a detailed breakdown of the timelines involved, our guide on how long Mounjaro takes to leave your system is a useful starting point, though the final decision depends on the type of surgery and the dose you are on.

Conception. Tirzepatide is not recommended during pregnancy or while trying to conceive. The MHRA advises using contraception throughout treatment and for a wash-out period before attempting conception. For women on oral contraceptives, NHS guidance also notes that absorption of the pill may be reduced during the first four weeks of treatment and for four weeks after each dose increase, an additional non-oral method is recommended during those windows. If you want to understand what that washout period looks like in practice, our page on how long until Mounjaro leaves your system explains the pharmacokinetics in plain terms, though clearance timing here is a clinical, not just a pharmacokinetic, question.

Switching medicines. Moving from tirzepatide to another GLP-1 medicine or vice versa requires careful overlap management. The relevant clearance information (including a broader look at how long tirzepatide takes to leave the system) should inform the conversation with your prescriber, who will review your full history before authorising any change. Our clinical team's background is outlined on the clinical team page if you want to understand who is reviewing that kind of decision.

Cost of treatment is a separate but fair question once you understand the clinical picture. Our Mounjaro price page explains what a transparent, all-inclusive private prescription involves. And if you are still weighing up treatment options more broadly, the treatment overview sets out what is currently licensed in the UK alongside diet and activity support.